Anthony G. Quinn Aeglea Bio Therapeutics, Inc. (AGLE) insider trading activity

Anthony G. Quinn is President & CEO of Aeglea BioTherapeutics, Inc.. Currently has a direct ownership of 550,540 shares of AGLE, which is worth approximately $15.2 Million. The most recent transaction as insider was on Mar 16, 2022, when has been sold 80,079 shares (Common Stock) at a price of $2.34 per share, resulting in proceeds of $187,385. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 551K

0% 3M change

0% 12M change

Total Value Held $15.2 Million

Anthony G. Quinn Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Mar 16 2022	BUY Open market or private purchase	$187,385 $2.34 p/Share	80,079 Added 12.7%	550,540 Common Stock
Mar 15 2022	BUY Open market or private purchase	$78,896 $1.86 p/Share	42,417 Added 8.22%	473,461 Common Stock
Mar 14 2022	BUY Open market or private purchase	$130,221 $1.93 p/Share	67,472 Added 13.53%	431,044 Common Stock
Mar 11 2022	BUY Open market or private purchase	$71,641 $2.06 p/Share	34,777 Added 8.73%	363,572 Common Stock
Dec 10 2021	BUY Open market or private purchase	$39,472 $3.75 p/Share	10,526 Added 3.1%	328,795 Common Stock
Dec 09 2021	BUY Open market or private purchase	$159,500 $3.7 p/Share	43,108 Added 11.93%	318,269 Common Stock

Also insider at

GBIO

Generation Bio Co. Healthcare

KLDO

Kaleido Biosciences, Inc. Healthcare

Director

AGQ

Anthony G. Quinn

President & CEO

Austin, TX

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells AGLE shares.

Notify only if

Value

Insider Trading

Get notified when an Aeglea Bio Therapeutics, Inc. insider buys or sells AGLE shares.

Notify only if

Operation

Value

Type

News

Receive news related to Aeglea BioTherapeutics, Inc.

Track Activities on AGLE

Account